"As a perfect addition to an already extremely positive year for CHEPLAPHARM, we were able to start another large project in 2018 with F....
CHEPLAPHARM Arzneimittel GmbH continues its successful expansion strategy by purchasing three further global niche products.
CHEPLAPHARM Arzneimittel GmbH continues with its diversification strategy.
CHEPLAPHARM is pleased to announce the acquisition of the commercial rights to ATACAND® (Candesartan Cilexetil) and ATACAND® Plus (fixed-dose...
From August 2018, CHEPLAPHARM expands its Ziegelhof headquarters in the Hanseatic city of Greifswald with a new building on an area of 5,300 square...
CHPLAPHARM Arzneimittel GmbH has successfully completed the refinancing of existing loans and promissory notes.
By acquiring the worldwide rights (except US) for the product VISUDYNE® from the Swiss Novartis Pharma AG, CHEPLAPHARM is now active in the...
In the course of an external credit rating, CHEPLAPHARM is rated B/B1 - and thus stable future outlooks.
CHEPLAPHARM Arzneimittel GmbH is pleased to announce that we have signed definitive agreements with Bristol-Myers Squibb to acquire product SOTALEX®.
Right at the beginning of the year, the fast-growing pharmaceutical company CHEPLAPHARM Arzneimittel GmbH secures the product rights for CYMEVENE®,...
Zurich (CH) / Greifswald (DE), December 15, 2017 – In a formal ceremony at the DKSH headquarters in Zurich, DKSH and CHEPLAPHARM Arzneimittel GmbH...
Archive
